Akari Therapeutics, Plc announced on July 23, 2025, its commitment to ongoing research into its novel spliceosome modulator, PH1, to further understand its effects on cancer. The company has demonstrated that PH1 may also act to inhibit key drivers in cancer tumors.
The PH1 payload has shown the ability to induce cytotoxicity in cancer cells under the influence of oncogenic drivers such as KRAS, BRAF, and FGFR3, as detailed in Patent WO2024220546A2. This expands the known mechanisms of action beyond its cytotoxic and immuno-oncology effects.
Abizer Gaslightwala, President and CEO of Akari, stated that the company is continuing to investigate how this novel payload may impact other key drivers relevant to cancer tumors. Preliminary data from additional preclinical research experiments testing PH1's activity against an established oncogenic driver unique to a major tumor are expected before year-end.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.